Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications

Cancer Lett. 2018 May 28:422:9-18. doi: 10.1016/j.canlet.2018.02.025. Epub 2018 Feb 20.

Abstract

Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of cancer-related deaths in American men. Due to its long latency period, PCa is considered as an ideal cancer type for chemopreventive interventions. Chemopreventive agents include various natural or synthetic agents that prevent or delay cancer development, progression and/or recurrence. Pre-clinical studies suggest that many natural products and dietary agents have chemopreventive properties. However, a limited number of these agents have been tested in clinical trials, with varying success. In this review, we have discussed the available clinical studies regarding the efficacy of natural chemopreventive agents against PCa, including tea polyphenols, selenium, soy proteins, vitamins and resveratrol. We have also provided a discussion on the clinical challenges and opportunities for the potential use of chemopreventive agents against PCa. Based on available literature, it appears that the variable outcomes of the chemopreventive clinical studies necessitate a need for additional studies with more rigorous designs and methodical interpretations in order to measure the potential of the natural agents against PCa.

Keywords: Chemoprevention; Clinical trials; Natural agents; Prostate cancer.

Publication types

  • Meta-Analysis
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Anticarcinogenic Agents / therapeutic use*
  • Biological Products / therapeutic use*
  • Chemoprevention*
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / etiology
  • Prostatic Neoplasms / prevention & control*

Substances

  • Anticarcinogenic Agents
  • Biological Products